Floatz logo

Midostaurin

Untreated Adult Acute Myeloid Leukemia

Mayo ClinicSmall moleculePhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Untreated Adult Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Daunorubicin
Wake Forest University Health Sciences
Phase 3BBB
Idarubicine
University of Nebraska
Phase 3BB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 3BB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 3BB
Valspodar
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Midostaurin is also rated in:

myelodysplastic syndrome with excess blasts-2Dormant
B
Indicative ·
62 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
62 / 100
View asset →
acute myeloid leukemia, FLT3 internal tandem duplicationDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →